The Latest Breaking News from FDA

U.S. health officials have approved a new Alzheimer’s drug that can modestly slow the disease

The blend of growth potential and stability in mid-cap pharma stocks is driven by rising demand for innovative therapies, strong economic conditions, and technological advancements that boost the sector's growth trajectory. Therefore, considering strong mid-cap stocks like Amphastar Pharmaceuticals (AMPH), Catalyst Pharmaceuticals (CPRX), and ACADIA Pharmaceuticals (ACAD), expected to soar…

 The decision comes weeks after the FDA authorized the marketing of the first menthol-flavored vaping products.

The Supreme Court announced Tuesday it will decide disputes over online access to pornography in Texas and FDA approval of vapes.

Given Organogenesis’s (ORGO) upbeat first-quarter results and promising development of its ReNu program for knee osteoarthritis, the company seems to be on the brink of significant growth. Let’s delve into its fundamentals to determine whether it's a hidden gem in the biotech sector. Read more to find out….

Two years after overturning Roe v. Wade, the Supreme Court takes on abortion once again. But its decisions may bring more restrictions in the long run

The resilience and lower volatility of consumer staples stocks make them reliable choices for long-term, steady growth. Thus, it could be wise to invest in fundamentally sound consumer staple stocks Colgate-Palmolive (CL), Altria Group (MO), and Kroger (KR) for the long haul. Read on.

Many of the recalled products contained a lead concentration more than 200 times greater than the FDA's guidance

With weight loss and diabetes drugs in high demand and short supply, potentially dangerous counterfeits have flooded the market.

Scientists found that contaminated milking equipment can harbor the H5N1 virus for more than an hour, increasing the risk of dairy farmers getting infected.

House Judiciary subcommittee hearing exposes concerns over FDA politicization during pandemic, raising questions about rushed vaccine approvals and adverse...